Histamine: A Novel Approach to Cancer Immunotherapy

References

• Mantovani A, Bottazzi B, Colotta F, et al. The origin and function of tumor-associated macrophages. Immunol Today 1992; 13: 265–270
   PubMedGoogle Scholar
• Mellstedt H., Frodin J, Ragnhammar E. P, et al. Therapy of colorectal carcinoma with monoclonal antibodies (MAb 17–1 A) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF). Acta Oncol 1991; 30: 923–931
   PubMed Web of Science ®Google Scholar
• Finke J H, Zea A H, Stanley J, et al. Loss of T-cell receptor zeta chain and p561ck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993; 53: 5613–5616
   PubMed Web of Science ®Google Scholar
• Mizoguchi H, O'Shea J J, Longo D L, et al. alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992; 258: 1795–1798
   PubMed Web of Science ®Google Scholar
• Nakagomi H., Petersson M, Magnusson I., et al. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993; 53: 5610–5612
   PubMed Web of Science ®Google Scholar
• Kono K, Salazar-Onfray F, Petersson M, et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity. Eur J Immunol 1996; 26: 1308–1313
   PubMed Web of Science ®Google Scholar
• Matsutla M., Petersson M, Lenkei R, et al. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer 1995; 61: 765–772
   PubMed Web of Science ®Google Scholar
• Kiessling R, Kono K, Petersson M, et al. Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules. Semin Immunopathol 1996; 18: 227–242
   PubMed Web of Science ®Google Scholar
• Bottazzi B, Walter S, Govino D, et al. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth and susceptibility to IL-2 therapy of a murine melanoma. J Immunel 1992; 148: 1280–1285
   PubMed Web of Science ®Google Scholar
• Hellstrand K, Hermodsson S. Synergistic NK cell activation by histamine and interleukin-2. Int Arch Allerg Appl Immunol 1990; 92: 379–389
   PubMedGoogle Scholar
• Hellstrand K, Kyletjord H, Asea A, et al. Regulation of the NK-cell response to IFN-α by biogenic amines. J Interferon Res 1992; 12: 199–206
   PubMedGoogle Scholar
• Hellstrand K, Asea A, Dahlgren C, et al. Histaminergic regulation of NK-cells: role of monocyte-derived, reactive oxygen metabolites. J Immunol 1994; 153: 4940–4947
   PubMed Web of Science ®Google Scholar
• Hansson M., Hermodsson S, Brune M, et al. Histamine protects T cells and NK cells against oxidative stress. J Interferon Cytokine Res 1999; 19: 1135–1144
   PubMed Web of Science ®Google Scholar
• Hansson M, Asea A, Ersson U, et al. Induction of apoptosis in natural killer cells by monocyte-derived reactive oxygen metabolites. J Immunol 1996; 156: 42–47
   PubMed Web of Science ®Google Scholar
• Hellstrand K, Hermodsson S. Histamine H2 receptor mediated regulation of human natural killer cell cytotoxicity. J Immunol 1986; 137: 656–660
   PubMed Web of Science ®Google Scholar
• Lynch N R, Salomon J C. Passive local anaphylaxis: demonstration of antitumor activity and complementation of intratumor BCG. J Natl Cancer Inst 1977; 58: 1093–1098
   PubMed Web of Science ®Google Scholar
• Burtin C, Scheinmann P, Salomon J C, et al. Decrease in tumour growth by injections of histamine or serotonin in fibrosarcoma-bearing mice: influence of H1 and H2 histamine receptors. Br J Cancer 1982; 45: 54–60
   PubMed Web of Science ®Google Scholar
• Tatsuta M, Lishi H, Ichii M, et al. Inhibitory effects of tetragastrin and histamine on carcinogenesis in the small intestines of W rats by N-methyl-N'-nitro-N-nitrosoguanidine. J Natl Cancer Inst 1986; 76: 277–281
   PubMed Web of Science ®Google Scholar
• Cricco G P., Davio C A, Bergoc R M, et al. Inhibition of tumor growth induced by histamine—in vivo and in vitro studies. Agents actions 1993; 38: C175–C177
   Google Scholar
• Suonio E., Tuomisto L, Alhava E. Effects of histamine, H1, H2 and Hic receptor antagonists and alpha-fluoromethylhistidine on the growth of human colorectal cancer in the subrenal capsule assay. Agents Actions 1994; 41: C118–C120
   PubMedGoogle Scholar
• dellaRovere F, Broccio G, Granata A, et al. In vivo experimental demonstration that hyperhistaminism counteracts tumor growth. Oncol Rep 1994; 1: 175–177
   PubMed Web of Science ®Google Scholar
• Rizell M, Lindner P, Hellstrand K, et al. Effect of histamine dihydrochloride on tumor growth rate and tumor blood flow. Int J Mi-crocirc 1997; 17: 98–105
   Google Scholar
• Hellstrand K, Asea A, Hermodsson S. Role of histamine in natural killer cell mediated resistance against tumor cells. J Immunol 1990; 145: 4365–4370
   PubMed Web of Science ®Google Scholar
• Adams W J, Lawson J A, Morris D L. Cimetidine inhibits growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth. Gut 1994; 35: 1632–1636
   PubMed Web of Science ®Google Scholar
• Gifford R R., Ferguson R M, Voss B V. Cimetidine reduction of tumour formation in mice. Lancet 1981; 8221: 638–640
   Google Scholar
• Gorczynski R M, Kennedy M, Ciampi A. Cimetidine reverses tumor growth enhancement of plasmacytoma tumors in mice demonstrating conditioned immunosuppression. J Immunol 1985; 134: 4261–4266
   PubMed Web of Science ®Google Scholar
• Caignard A, Martin M, Reisser D, et al. Effects of Cimetidine and indomethacin on the growth of dimethylhydrazine-induced or transplanted intestinal cancers in the rat. Br J Cancer 1984; 50: 661–665
   PubMed Web of Science ®Google Scholar
• Lawson J A, Adams W J, Morris D L. Ranitidine and Cimetidine differ in their in vitro and in vivo effects on human colonic cancer. Br J Cancer 1996; 73: 872–876
   PubMed Web of Science ®Google Scholar
• Mandanas R, Schultz S, Scullin D, et al. Phase II trial of cimetidine in metastatic melanoma. A Hoosier Oncology Group trial. Am J Clin Oncol 1991; 14: 397–399
   PubMed Web of Science ®Google Scholar
• Creagan E T, Ahmann D L, Green S J, et al. Phase II study of recombinant leukocyte A interferon (IFN-rA) plus Cimetidine in disseminated malignant melanoma. J Clin Oncol 1985; 3: 977–981
   PubMed Web of Science ®Google Scholar
• Links M, Clingan P R, Phadke K, et al. A randomized trial of cimetidine with 5–fluorouracil and folinic acid in metastatic colorectal cancer. Eur J Surg Oncol 1995; 21: 523–525
   PubMedGoogle Scholar
• Fielding J W. H2 antagonists for gastric cancer: small numbers are not beautiful. Gut 1998; 42: 9
   PubMed Web of Science ®Google Scholar
• Nielsen H J, McArdle C D, Moesgaard F. The effect of ranitidine on long-term survival in primary colorectal cancer—a 40 month interim analysis. GI Cancer 1998; 2: 227–233
   Web of Science ®Google Scholar
• Brunda M, Bellantoni J. D, Sulich V. In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer 1987; 40: 365–371
   PubMed Web of Science ®Google Scholar
• Asea A, Hermodsson S, Hellstrand K. Histaminergic regulation of natural killer-cell-mediated clearance of tumor cells in mice. Scand J Immunol 1996; 43: 9–15
   PubMed Web of Science ®Google Scholar
• Hellstrand K, Hermodsson S, Brune M, et al. Histamine in cancer immunotherapy. Scand J Clin Lab Invest 1997; 57: 193–202
   PubMed Web of Science ®Google Scholar
• Johansson S, Landström M, Hellstrand K, et al. The response of Dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation. Br J Cancer 1998; 77: 1213–1219
   PubMed Web of Science ®Google Scholar
• Keilholz U, Conradt C, Legha S S, et al. Results of interleukin-2–based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998; 16: 2921–2929
   PubMed Web of Science ®Google Scholar
• Oldharn R K, Blumenschein G, Schwartzberg L. Combination biotherapy utilizing interleukin-2 and a interferon in patients with advanced cancer: a National Biotherapy Study Group Trial. Mol Biother 1992; 4: 4–9
   PubMedGoogle Scholar
• Villikka K, Pyrhonen S. Cytokine therapy of malignant melanoma. Ann Med 1996; 28: 227–233
   PubMed Web of Science ®Google Scholar
• Hellstrand K., Naredi P, Lindnér P, et al. Histamine in immunotherapy of advanced melanoma. A pilot study. Cancer Immunol Immunother 1994; 39: 416–419
   PubMed Web of Science ®Google Scholar
• Swansbury G J, Lawler S D, Alimena G, et al. Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet 1994; 73: 1–7
   PubMed Web of Science ®Google Scholar
• Thalhammer F, Geissler K., Jager U, et al. Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study. Ann Hematol 1996; 72: 216–222
   PubMed Web of Science ®Google Scholar
• Hellstrand K, Mellqvist U H., Wallhult E, et al. Histamine and interIeukin-2 in acute myelogenous leukemia. Leuk Lymph 1997; 27: 429–438
   PubMed Web of Science ®Google Scholar
• Shepherd J D, Jacky E, Grathwohl A, et al. Phase II study of subcutaneous rHu IL-2 in patients with acute myelogenous leukemia in partial or complete second remission and partial relapse. Br J Haematol 1994; S87: 205
   Google Scholar
• Bergmann L, Heil G, Kolbe K, et al. Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblas-tic leukemia. Leuk Lymph 1995; 16: 271–279
   PubMed Web of Science ®Google Scholar
• Meloni G, Vignetti M, Pogliani E, et al. Interleukin-2 therapy in relapsed acute myelogenous leukemia. Cancer J Sci Am 1997; 3(Suppl l)43–47
   Google Scholar
• Brune M, Hellstrand K. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukemia. Br J Haematol 1996; 92: 620–626
   PubMed Web of Science ®Google Scholar
• Brune M, Hansson M, Mellqvist U H, et al. NK-cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites. Eur J Haematol 1996; 57: 312–319
   PubMed Web of Science ®Google Scholar
• Whiteside T, Vujanovic N L, Herberman R B. Natural killer cells and tumor therapy. Curr Top Mierobiol Immunol 1998; 230: 221–244
   PubMed Web of Science ®Google Scholar
• Belldegrun A, Tso C L., Kaboo R, et al. Natural immune reactivity-associated therapeutic response in patients with metustatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and IL-2–based therapy. 1 Immunother Emphasis Tumor Immunol 1996; 19: 149–161
   PubMed Web of Science ®Google Scholar
• Gohring B, Riemann D, Rebmann U, et al. Prognostic value of immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha in combination with 5–FLJ. Urol Res 1996; 24: 297–303
   PubMed Web of Science ®Google Scholar
• Wersäll P, Mellstedt H. Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide. IL-2 and alpha-IFN. Med Oncol 1995; 12: 69–77
   PubMed Web of Science ®Google Scholar
• Mitchell M S. Chemotherapy in combination with biomodulation: a 5–year experience with cyclophosphamide and IL-2. Semin Oncol 1992; 19(Suppl 4)80–87
   PubMedGoogle Scholar
• Håkansson A, Gustafsson G, Krysander L., et al. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer 1996; 74: 670–676
   PubMed Web of Science ®Google Scholar
• Buggins A G., Hirst W J, Pagliuca A, et al. Variable expression of CD3–zeta and associated protein tyrosine kinases in lymphocytes from patients with myeloid malignancies. Br J Haematol 1998; 100: 784–792
   PubMed Web of Science ®Google Scholar
• Hellstrand K, Brune M, Mellqvist U H, et al. Histamine. cimetidine and colorectal cancer. Nat Med 1996; 2: 364–365
   PubMed Web of Science ®Google Scholar